PIK3CA and ESR1 mutations detection of CTCs in peripheral blood of breast cancer patients using ARMS-PCR HRMA

• Genes: PIK3CA, ESR1
• Methodology: ARMS-PCR HRMA
• Instrumentation: LightCycler 2.0 (IVD, Roche Diagnostics)
• Analytical characteristics: exceptional analytical sensitivity and specificity
• Requested sample: 20mL peripheral blood (EDTA) - pre-, during or post-therapy 
• Cost: please contact Dr E.Lianidou (lianidou@chem.uoa.gr)

• Publications:

1. Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V, Lianidou E. PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer. Clin Cancer Res 2014;20:5823-34
2. Markou A, Tzanikou E, Ladas I, Makrigiorgos M, Lianidou ES. NaME-PrO-assisted ARMS (NAPA): a novel approach for the improvement of ARMS-PCR specificity in liquid biopsies. Anal Chem 2019 Oct 15;91:13105-13111

• Clinical Importance: Mutations in PIK3CA are correlated with the response to therapy with HERCEPTIN (trastuzumab) in HER-2 positive breast cancer patients

PubMed, 315 publications, 14/11/19

http://www.ncbi.nlm.nih.gov/pubmed/?term=HER-2+PIK3CA+mutations